Peptide Association
Start Your Consultation
All peptides
PainFDA Approved

Ziconotide (Prialt)

Intrathecal infusion
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

A synthetic 25-amino acid peptide identical to omega-conotoxin MVIIA, a neurotoxin found in the venom of the marine cone snail Conus magus. Ziconotide selectively and reversibly blocks N-type voltage-gated calcium channels (Cav2.2) in the dorsal horn of the spinal cord, inhibiting neurotransmitter release from primary afferent nociceptive neurons.

Mechanism of Action

It provides analgesia without opioid receptor activation, tolerance development, or respiratory depression.

Research Summary & Key Findings

FDA-approved in 2004 for severe chronic pain in patients refractory to or intolerant of systemic analgesics, adjunctive therapies, or intrathecal morphine. Requires intrathecal administration via implanted infusion pump. Clinical trials demonstrated significant pain reduction in patients with cancer pain and non-malignant pain syndromes. Narrow therapeutic index with dose-limiting neuropsychiatric side effects (cognitive impairment, hallucinations, psychosis) requires careful titration.

Clinical Status

FDA Approved

Ziconotide (Prialt) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Intrathecal infusion

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Pain

Difelikefalin (Korsuva)

FDA Approved

A selective kappa-opioid receptor (KOR) agonist peptide that does not cross the blood-brain barrier, providing periphera...

View details

ARA-290

In Clinical Trials

A synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) that selectively activates the inna...

View details

Palmitoylethanolamide (PEA)

Research Phase

An endogenous fatty acid amide belonging to the N-acylethanolamine family, naturally produced by cells in response to ti...

View details

Dynorphin A

Research Phase

Dynorphin A is an endogenous opioid peptide of 17 amino acids that preferentially binds to and activates kappa-opioid re...

View details

Start Your Consultation

Get an AI-proposed Ziconotide (Prialt) protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Ziconotide (Prialt).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.